Camizestrant with palbociclib for untreated oestrogen receptor-positive HER2-negative metastatic breast cancer after adjuvant endocrine treatment [ID6534]
Awaiting development
Reference number: GID-TA11686
Expected publication date: TBC
Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the evaluation will begin during mid May 2027 when we will write to stakeholders about how they can get involved. The deadline for submissions is expected in approximately mid July 2027.